Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-06-17

FDA Approved: SUBOXONE — Supplemental Application (INDIVIOR INC.)

View source ↗

Summary

The FDA approved a supplemental application for SUBOXONE (buprenorphine hydrochloride/naloxone hydrochloride) submitted by Indivior Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SUBOXONE (buprenorphine hydrochloride, naloxone hydrochloride)

Snippet

SUPPL AP for SUBOXONE (BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE)